Idt Australia Limited · ASX:IDT
Idt Australia — H1 FY2024 Earnings Presentation
21 slides from Idt Australia's earnings presentation, Feb 21, 2024
Slide 1: IDT Australia Interim Results 1HFY24
IDT Australia I N T E R I M R E S U L T S | 1 H F Y 2 4
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 3: Agenda
1 FIRST-HALF ACCOMPLISHMENTS 2 CORE BUSINESS PILLARS Our business 3 Agenda ACHIEVEMENTS OVER THE PAST YEAR Outlook 4 LARGE ADDRESSABLE MARKETS 5 OUTLOOK
Slide 4: First-Half Accomplishments
BUILDING SHAREHOLDER VALUE First-Half Accomplishments 4 4 IDT Australia INTERIM RESULTS | 1HFY24 IDT Australia INTERIM RESULTS | 1HFY24
Slide 5: First-half Accomplishments: Building Shareholder Value
First-half S A L E S P I P E L I N E Accomplishments Positive outlook backed by strong growth in potential sales pipeline Building G R O W T H Building Shareholder Value Shareholder Value Momentum carrying through to 2H with K E Y V E R T I C A L S more growth expected Share Price Performance – Fina
Slide 6: 1HFY24 Revenue Jumps 137%
1HFY24 Revenue R E V E N U E G R O W T H Jumps 137% 137% Total revenue in 1HFY24 jumps 137% PCP to $5.8M Strong sales pipeline supports further growth over coming periods Strong Start REVENUE To 2024 P R O P O S A L S L E A D S Value of proposals submitted in 1HFY24 Early-stage leads jumped to 133 i
Slide 7: Further Growth Expected
G R O W T H R E V E N U E T R E A T M E N T S T H E R A P I E S Further revenue growth expected as growth API business is the standout Specialty Orals interim revenue expanded 12% to $2.2M as Advanced Therapies (AT) vertical interim accelerates in higher margin complex with interim revenue of $2.8M
Slide 8: Core Business Pillars
Core Business Pillars IDT Australia’s Business Divisions R & D Supplementary services supporting all 3 business pillars Active Pharmaceutical Ingredient (API) Finished Dosage Forms (FDFs) The active component which produces the required effect in drugs A drug product in the final form that can be ad
Slide 9: API Manufacturing
R E V E N U E J U M P S C L I E N T S A P I S A L E S A P I V E R T I C A L Revenue jumps 985% to $2.8M Clients increasingly turning to IDT for Interest in AT and Specialty Orals THE API vertical represents 53% of in 1HFY24 vs. PCP one-stop offering from development of offerings are restimulating in
Slide 10: Advanced Therapies
Advanced Therapies M A R K E T I N T E R E S T C O N T R A C T S I N V E S T M E N T Growing Demand & Strong market interest – vertical Secured $6.1M in customer contracts, Alignment of growth drivers with Limited Supply accounts for 61% of total proposal including for ADC linkers – a hot global gov
Slide 11: Good Manufacturing Practice
G O O D M A N U F A C T U R I N G P R A C T I C E IDT is one of few automated large-scale Good Manufacturing Practice (GMP) production facility in Australia. It has the licensure, capabilities and facilities to manufacture a range of medicinal cannabis products for local and international markets. 1
Slide 12: Specialty Orals
Specialty Orals Market Leader & Competitive Edge R E V E N U E I N C R E A S E T R E A T M E N T S N E W C O N T R A C T S Interim revenue increases 12.2% to $2.2M despite Strong demand for psychedelic and other CNS IDT continues to sign new contracts, including a slowdown in orders from one major m
Slide 13: Specialty Orals (continued)
Specialty Orals Market Leader & Competitive Edge (continued) I N C R E A S E D D E M A N D I N C R E A S E D D E M A N D R A P I D G R O W T H Medcan revenue set to recover as industry clears Orals will continue to be a key revenue contributor Leveraged to rapid growth in mental illness “stale” inve
Slide 14: Well Placed to Grow in 2024 and Beyond
ACHIEVEMENTS OVER THE PAST YEAR WELL PLACED TO GROW IN 2024 AND BEYOND WELL PLACED TO GROW IN 2024 AND BEYOND Well Placed to Grow in 2024 and Beyond G R O W T H D R I V E R S I N F Y 2 4 A N D B E Y O N D 14 IDT Australia INTERIM RESULTS | 1HFY24 14 IDT Australia INTERIM RESULTS | 1HFY24
Slide 15: Achievements Over The Past Year
Achievements Over The Past Year R E T U R N T O G R O W T H ✓ Deliver improved quarterly revenues S T R A T E G I C Well Placed to Grow P I V O T In 2024 and Beyond ✓ Harness operating leverage to drive profitability as the business scales U N L O C K N E W ✓ Successfully completed a $7M capital v O
Slide 16: Largest Addressable Markets: Advanced Therapies
A S E P T I C F I L L & F I N I S H ( A D C & m R N A ) Largest Addressable $13.1B $3.4B $805M Markets: T A M S A M S O M Advanced Global market forecast to hit US$13.1B Forecast to reach ~US$3.4B by 2026, Estimated on site capacity and future Therapies by 2026 (22% CAGR)1 representing part of the T
Slide 17: Largest Addressable Markets: Specialty Orals
M E D I C A L C A N N A B I S & P S Y C H E D I L I C S Largest Addressable $64B $57B $72M Markets: T A M S A M S O M Specialty Orals Global market forecast to hit US$64B Forecast to reach ~US$57B by 2026, Estimated using site at ~$US72M by by 2026 (18.1% CAGR)2,3 representing part of the TAM that c
Slide 18: Largest Addressable Markets: API Manufacturing
A P I P R O D U C T I O N Largest Addressable $250B $199B $18M Markets: T A M S A M S O M API Manufacturing Global market forecast to hit US$250B Forecast to reach ~US$199B by 2026, Estimated using current site capacity by 2026 (6.4% CAGR)4 representing part of the TAM that can only, conservatively
Slide 19: Growth Outlook
Growth Outlook G R O W T H D R I V E R S I N F Y 2 4 A N D B E Y O N D 19 IDT Australia INTERIM RESULTS | 1HFY24
Slide 20: Growth Outlook Drivers in FY24 and Beyond
Growth Outlook Drivers in FY24 and Beyond T R I P L E O P P O R T U N I T I E S C A S H F L O W M I L E S T O N E Sales pipeline continues to grow with 188 leads On track to deliver first quarter of positive and ~$25M in proposals operating cash flow before end of CY24 O R G A N I C T A I L W I N D
Slide 21: Our Glossary
Our A D C M D M A Methylene-dioxy-meth-amphetamine Antibody Drug Conjugate Glossary A P I Active Pharmaceutical Ingredient O D C Office of Drug Control A S P Aseptic Sterile Processing P T S D Post Traumatic Stress Disorder Acronym C D M O Contract Development Manufacturing Organisation S A S Specia